IL10 and B-cell chronic lymphocytic leukemia: Besides IL‐10, we targeted the CXCR4/CXCL12 axis, due to its important role in stromal‐dependent resistance to therapy, further contributing to an immunosuppressive TME, which may impair CAR T‐cell function in CLL.